China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...

The firm also announced that it was divesting most of its equity interest in Shanghai Hutchison Pharmaceuticals to invest in its own pipeline.

Hutchmed (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around $608 million as the ...

In a move designed to advance its pipeline and its “innovative medicines business,” Chinese biotech Hutchmed will ...

Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment ...

Limited ($HK:0013), backed by Hong Kong billionaire Li Ka-Shing, gained nearly 4% today after it agreed to sell ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Biopharmaceutical firm Hutchmed China Ltd., backed by Hong Kong billionaire Li Ka-shing, saw its shares rally on Thursday ...

Hutchmed sells a 45% stake in SHPL for $608 million and focuses on advancing its cancer and immunology pipeline, including ...

(Alliance News) - Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd to GP Health Service Capital Co Ltd and Shanghai Pharmaceuticals ...

HUTCHMED (China) has entered into agreements to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals (SHPL) ...

HUTCHMED (China), controlled by tycoon Li Ka-shing, is selling stakes in its health subsidiary for around US$608 million as ...